Description
Mektovi is a kinase inhibitor used in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation.
Recommended Dosage: The recommended dosage of Mektovi is 45 mg taken orally twice daily, approximately 12 hours apart, in combination with encorafenib. Treatment should continue until disease progression or the occurrence of unacceptable toxicity.
Tablets may be taken with or without food. If a dose is missed, do not take it within 6 hours of the next scheduled dose of Mektovi. If vomiting occurs after taking the tablets, do not take an additional dose; instead, continue with the next scheduled dose.
Note: Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before starting treatment with Mektovi.
Reviews